PAG invests $200m in India's RK Pharma
PAG has invested USD 200m in RK Pharma, a US-headquartered generic drug maker with significant operations in India.
India’s HealthifyMe raises $30m
LeapFrog Investments and Khosla Ventures have led a USD 30m pre-Series D round for India-based mobile health and fitness app HealthifyMe.
Bain boosts take-private offer for Australia's Estia
Bain Capital has increased its take-private offer for Australia-listed aged care provider Estia Health – to a point where the business is valued at about AUD 826.8m (USD 550m) – after an earlier bid was rejected.
NewQuest, GIC back Everbridge's South Asia continuation fund
NewQuest Capital Partners and GIC have supported a USD 267m continuation fund for Capital Group Private Markets spinout Everbridge Partners, two years after a larger deal involving some of the same assets failed to close amid portfolio volatility.
Hong Kong's AIA commits $200m to LeapFrog
Hong Kong-listed insurance company AIA Group has agreed to commit USD 200m to various funds managed by LeapFrog Investments, a UK-based impact investor with an extensive Asia footprint.
Australia's PE-backed Silk Laser set for take-private
Australia-listed Silk Laser Clinics, a non-surgical aesthetics business backed by local PE firm Advent Partners, has signalled it intends to accept a take-private offer from Hong Kong’s EC Healthcare.
Kazakhstan investor backs TVM SE Asia healthcare fund
Qazaqstan Investment Corporation (QIC), a private equity fund-of-funds set up by the Kazakhstan government, has invested in a Southeast Asia fund managed by TVM Capital Healthcare.
Australia's GenesisCare files for US bankruptcy protection
GenesisCare, an Australia-headquartered cancer care provider in which KKR holds a minority stake, has filed for bankruptcy protection in the US and announced a restructuring that will separate US operations from those in Australia, Spain, and the UK.
HighLight updates final close timeline for China healthcare fund
HighLight Capital, a Chinese life sciences investor, has pushed out the final close on its fourth US dollar-denominated fund to the third quarter amid challenging fundraising conditions for the industry.
Japan's Heartseed raises $14m Series D
Heartseed, a Tokyo-based biotech start-up specializing in treatments that use cardiac muscle cells to initiate the remuscularization of patients who have suffered heart failure, has raised JPY 2bn (USD 14.3m) in Series D funding.
China's Biomissile secures $28m Series B
Suzhou-based Biomissile has raised CNY 200m (USD 28m) in a Series B funding round led by Kequan Capital. Existing investor Fosun Health Capital re-upped.
Singapore digital health start-up Ora raises $10m
Singapore-based digital health start-up Ora has raised a USD 10m Series A round led by TNB Aura and Antler. Other participants include Gobi Partners, Kairous Capital, and GMA Ventures.
Qiming hits $930m final close on latest renminbi fund
Qiming Venture Partners has closed its seventh renminbi-denominated fund on CNY 6.5bn (USD 930m), marking what it claims is China's largest local currency fundraise of 2023 to date
China's Drug Farm secures $27m in first tranche of Series C
Drug Farm, a China and US-based developer of treatments for infection and immunological diseases, has raised USD27m in the first tranche of Series C funding led by Shanghai's YD Capital.
South by Southeast: Asia’s next growth engine?
Grouping together markets based on growth and scale is a problematic with South Asia and Southeast Asia as it was with the BRIC economies. But to some extent, investors are buying into the story
China's Coherent Biopharma raises $100m
Chinese cancer-focused biotech developer Coherent Biopharma has raised about USD 100m in Series B funding featuring HM Capital.
IDG leads $59m Series A for China’s Taichu Biotech
Shanghai Taichu Biotechnology, a China-based outsourced drug developer focused on novel treatments, has raised a serious A of CNY 400m (USD59m) led by IDG Capital.
China insurance tech player raises $43m
Shanghai Kingstar Winning Software, a digital risk control solution provider for insurers, has raised a Series C round of CNY300m (USD 43m) led by China Taiping Insurance Group.
Quadria acquires Malaysia’s Straits Orthopaedics
Singapore-headquartered healthcare specialist Quadria Capital has acquired a majority stake in Malaysian contract devices manufacturer Straits Orthopaedics at an enterprise value of USD 240m.
Eight Roads leads $38m round for China biotech player Adcentrx
China and US-based biotech company Adcentrx has raised USD38m in an extended Series A round led by Eight Roads Ventures, with participation from F-Prime Capital, ABio-X, Delta Capital, and Trinity Innovation Fund.
Deal focus: CBC gets counterintuitive in China
CBC Group has helped multiple start-ups move from in-licensing to drug development to commercialisation. With China’s Hasten, it is navigating this tried-and-tested journey in reverse
GL Capital leads $290m investment in China’s Sangon Biotech
Chinese healthcare-focused private equity firm GL Capital has led a CNY2bn (USD 290m) investment in local life sciences company Sangon Biotech.
CBC, Mubadala lead $315m round for China's Hasten Biopharma
Specialist healthcare investor CBC Group and Mubadala Investment have led a USD 315m round for China-based Hasten Biopharmaceutic, with participation from other undisclosed institutional investors.
China dental 3D printing company raises $34m
Chinese dental 3D printing company Chamlion Technology has raised CNY 236m (USD 34m) in Series B funding from Vertex Ventures, 3H Health Investment, and Zhencheng Investment.